yap1 polyclonal antibody  (Bioss)

Journal: Scientific Reports

Article Title: LBPs NPs suppress breast cancer progression by inhibiting YAP1 expression to induce ferroptosis and alter energy metabolism

doi: 10.1038/s41598-025-34454-w

Figure Lengend Snippet: LBPs suppress the malignant phenotype of human mammary epithelial cells induced by YAP1 overexpression. ( A ) RT-qPCR analysis of the relative mRNA expression of YAP1 in MCF 10A cells after transfection with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. ( B , C ) Colony formation assays were used to evaluate the proliferative capacity of MCF 10A cells after LBPs treatment or transfection with a YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. ( D ) Flow cytometry was employed to quantify apoptosis in MCF 10A cells following LBPs treatment or transfection with a YAP1 -overexpression plasmid. ( E , F ) Actin-Tracker Green-488 probes were employed to visualize F-actin architecture in MCF 10A cells following LBPs treatment or transfection with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. Scale bar, 50 μm. ( G , H ) Transwell assays were performed to evaluate the invasive capacity of MCF 10A cells after LBPs treatment or transfection with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. Scale bar, 200 μm.

Article Snippet: After incubation with goat serum for 30 min, cells were incubated overnight with the following antibodies: YAP1 (1:100; bs-3605R; Bioss, Beijing, China).

Techniques: Over Expression, Quantitative RT-PCR, Expressing, Transfection, Plasmid Preparation, Flow Cytometry

Journal: Scientific Reports

Article Title: LBPs NPs suppress breast cancer progression by inhibiting YAP1 expression to induce ferroptosis and alter energy metabolism

doi: 10.1038/s41598-025-34454-w

Figure Lengend Snippet: LBPs abrogate YAP1 -overexpression-induced augmentation of mitochondrial function and upregulation of related factor expression in human mammary epithelial cells. ( A , B ) MMP changes were assessed with the JC-1 fluorescent probe in MCF 10A cells following LBPs treatment or transfection with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. Scale bar, 50 μm. ( C , D ) Representative fluorescence images illustrating ATP probe expression after transfection of pCMV-Mito-AT1.03 into MCF 10A cells that had been subjected to LBPs treatment or transfected with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. Scale bar, 50 μm. ( E , F ) RT-qPCR analysis of the relative mRNA expression of YAP1 and TAZ in MCF 10A cells following LBPs treatment or transfection with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. ( G ) Western blot analysis of YAP1 , TAZ , MMP2 , MMP9 , Vimentin protein expression in MCF 10A cells following LBPs treatment or transfection with the YAP1 -overexpression plasmid. ( H – L ) The gray blots were analyzed with ImageJ software ( n = 3). *** P < 0.001.

Article Snippet: After incubation with goat serum for 30 min, cells were incubated overnight with the following antibodies: YAP1 (1:100; bs-3605R; Bioss, Beijing, China).

Techniques: Over Expression, Expressing, Transfection, Plasmid Preparation, Fluorescence, Quantitative RT-PCR, Western Blot, Software

Journal: Scientific Reports

Article Title: LBPs NPs suppress breast cancer progression by inhibiting YAP1 expression to induce ferroptosis and alter energy metabolism

doi: 10.1038/s41598-025-34454-w

Figure Lengend Snippet: LBPs suppress YAP1 -overexpression-driven malignant progression of breast cancer cells. ( A ) RT-qPCR analysis of the relative mRNA expression of YAP1 in MDA-MB-231 cells after transfection with YAP1 -siRNA. Data are presented as the mean ± SD ( n = 3), *** P < 0.001, ** P < 0.01. ( B , C ) Colony formation assays were used to evaluate the proliferative capacity of MDA-MB-231 cells after LBPs treatment or transfection with a YAP1 -overexpression plasmid or YAP1 -siRNA. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. ns: not significant. ( D , E ) Representative TUNEL staining images of MDA-MB-231 cells after LBPs treatment, transfection with the YAP1 -overexpression plasmid, or YAP1 -siRNA. Red fluorescence indicates TUNEL-positive cells and blue fluorescence denotes nuclei. Data are presented as the mean ± SD ( n = 3), *** P < 0.001, ** P < 0.01, ns: not significant. Scale bar, 200 μm. ( F , G ) Actin-Tracker Green-488 probes were employed to visualize F-actin architecture in MDA-MB-231 cells after LBPs treatment, transfection with the YAP1 -overexpression plasmid, or YAP1 -siRNA. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. ns: not significant. Scale bar, 50 μm. ( H , I ) Transwell assays were performed to evaluate the invasive capacity of MDA-MB-231 cells after LBPs treatment, transfection with the YAP1 -overexpression plasmid, or YAP1 -siRNA. Data are presented as the mean ± SD ( n = 3), *** P < 0.001, ** P < 0.01, ns: not significant. Scale bar, 200 μm.

Article Snippet: After incubation with goat serum for 30 min, cells were incubated overnight with the following antibodies: YAP1 (1:100; bs-3605R; Bioss, Beijing, China).

Techniques: Over Expression, Quantitative RT-PCR, Expressing, Transfection, Plasmid Preparation, TUNEL Assay, Staining, Fluorescence

Journal: Scientific Reports

Article Title: LBPs NPs suppress breast cancer progression by inhibiting YAP1 expression to induce ferroptosis and alter energy metabolism

doi: 10.1038/s41598-025-34454-w

Figure Lengend Snippet: LBPs abrogate YAP1 -overexpression-induced augmentation of mitochondrial function and upregulation of related factor expression in breast cancer cells. ( A , B ) MMP changes were assessed with the JC-1 fluorescent probe in MDA-MB-231 cells after LBPs treatment, transfection with the YAP1 -overexpression plasmid, or YAP1 -siRNA. Data are presented as the mean ± SD ( n = 3). *** P < 0.001, ns: not significant. Scale bar, 50 μm. ( C , D ) Representative fluorescence images illustrating ATP probe expression after transfection of pCMV-Mito-AT1.03 into MDA-MB-231 cells that had been subjected to LBPs treatment or transfected with the YAP1 -overexpression plasmid, or YAP1 -siRNA. Data are presented as the mean ± SD ( n = 3). *** P < 0.001, ns: not significant. Scale bar, 50 μm. ( E , F ) RT-qPCR analysis of the relative mRNA expression of YAP1 and TAZ in MDA-MB-231 cells following LBPs treatment or transfection with the YAP1 -overexpression plasmid or YAP1 -siRNA. Data are presented as the mean ± SD ( n = 3), *** P < 0.001, ** P < 0.01, * P < 0.05, ns: not significant. ( G ) Western blot analysis of YAP1 , TAZ , ACSL4 and GPX4 protein expression in MDA-MB-231 cells following LBPs treatment or transfection with the YAP1 -overexpression plasmid or YAP1 -siRNA. ( H– K ) The gray blots were analyzed with ImageJ software ( n = 3). *** P < 0.001, ** P < 0.01, * P < 0.05, ns: not significant. ( L , M ) Detection of mitochondrial Fe 2+ levels using Mito-FerroGreen probe. Data are presented as the mean ± SD ( n = 3), *** P < 0.001, ns: not significant. Scale bar, 100 μm.

Article Snippet: After incubation with goat serum for 30 min, cells were incubated overnight with the following antibodies: YAP1 (1:100; bs-3605R; Bioss, Beijing, China).

Techniques: Over Expression, Expressing, Transfection, Plasmid Preparation, Fluorescence, Quantitative RT-PCR, Western Blot, Software

Journal: Scientific Reports

Article Title: LBPs NPs suppress breast cancer progression by inhibiting YAP1 expression to induce ferroptosis and alter energy metabolism

doi: 10.1038/s41598-025-34454-w

Figure Lengend Snippet: Characterization of LBPs-NPs and their capacity to suppress YAP1 -overexpression-induced malignant progression. ( A , B ) Size distribution of PLGA NPs and LBPs NPs. ( C ) TEM images of PLGA NPs and LBPs NPs. ( D ) Representative fluorescence microscopy images of MDA-MB-231 cells treated with FITC-LBPs and FITC-LBPs NPs. The blue signal represents nucle stained with DAPI and the green signal represents FITC. Scale bar, 30 μm. ( E , F ) Colony formation assays were used to evaluate the proliferative capacity of MDA-MB-231 cells after LBPs or LBPs NPs treatment or transfection with a YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. ( G ) Flow cytometry was employed to quantify apoptosis in MDA-MB-231 cells following LBPs or LBPs NPs treatment or transfection with a YAP1 -overexpression plasmid. ( H , I ) Actin-Tracker Green-488 probes were employed to visualize F-actin architecture in MDA-MB-231 cells following LBPs or LBPs NPs treatment or transfection with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. Scale bar, 40 μm. ( J , K ) Transwell assays were performed to evaluate the invasive capacity of MDA-MB-231 cells after LBPs treatment or transfection with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001, ** P < 0.01. Scale bar, 200 μm.

Article Snippet: After incubation with goat serum for 30 min, cells were incubated overnight with the following antibodies: YAP1 (1:100; bs-3605R; Bioss, Beijing, China).

Techniques: Over Expression, Fluorescence, Microscopy, Staining, Transfection, Plasmid Preparation, Flow Cytometry

Journal: Scientific Reports

Article Title: LBPs NPs suppress breast cancer progression by inhibiting YAP1 expression to induce ferroptosis and alter energy metabolism

doi: 10.1038/s41598-025-34454-w

Figure Lengend Snippet: LBPs NPs suppressed the expression of YAP1 and TAZ, and promoted the expression of p-YAP1 and ferroptosis. ( A , B ) Prussian blue staining for the detection of non-heme Fe 2+ in MDA-MB-231 cells after LBPs treatment or transfection with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001, * P < 0.05. Scale bar, 50 μm. ( C ) Western blot analysis of YAP1 , p-YAP1, TAZ , ACSL4 and GPX4 protein expression in MDA-MB-231 cells following LBPs or LBPs NPs treatment or transfection with the YAP1 -overexpression plasmid. ( D– H ) The gray blots were analyzed with ImageJ software ( n = 3). ** P < 0.01, *** P < 0.001. ( I ) Western blot analysis of ACSL4 and GPX4 protein expression in MDA-MB-231 cells following the treatment of LBPs NPs or LBPs NPs plus Ferrostatin-1. ( J , K ) The gray blots were analyzed with ImageJ software ( n = 3). *** P < 0.001. ( L ) Immunofluorescence staining analysis of YAP1 expression in MDA-MB-231 cells following LBPs or LBPs NPs treatment. ( M ) Quantification of YAP1 expression levels. Data are presented as the mean ± SD ( n = 3), *** P < 0.001, ** P < 0.01, * P < 0.05. Scale bar, 50 μm.

Article Snippet: After incubation with goat serum for 30 min, cells were incubated overnight with the following antibodies: YAP1 (1:100; bs-3605R; Bioss, Beijing, China).

Techniques: Expressing, Staining, Transfection, Over Expression, Plasmid Preparation, Western Blot, Software, Immunofluorescence